Immunomedics Inc

Immunomedics — Proxy Contest (January 2017)

29 slides from Immunomedics's proxy contest presentation, Jan 27, 2017

  1. Slide 1: The Right Board and the Right Strategy to Maximize Stockholder Value

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 IMMUNOMEDICS, INC. Advanced Antibody - Based Therapeutics Oncology Autoimmune Diseases January 2017 The Right Board and the Right Strategy to Maximize

  2. Slide 2: Important Additional Information / Forward Looking Statements

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Important Additional Information / Forward Looking Statements Important Additional Information Immunomedics , Inc. (the “Company”), its directors and

  3. Slide 3: Agenda

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Agenda 3 • Well - Positioned to Expeditiously Maximize Stockholder Value • New , Highly Respected, Experienced and Completely Independent Board Focuse

  4. Slide 4: Well-Positioned to Expeditiously Maximize Stockholder Value

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Well - Positioned to Expeditiously Maximize Stockholder Value 4

  5. Slide 5: Overview and Financial Highlights

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 5 Overview and Financial Highlights Common shares outstanding 106 million Market capitalization $460 million Debt (convertible senior notes) $100 mill

  6. Slide 6: Critical near-term milestones achieved

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 • Immunomedics has achieved a number of critical near - term milestones : – Added four highly respected, ideally qualified and completely independent

  7. Slide 7: IMMU-132 (sacituzumab govitecan) late-stage therapy

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 • IMMU - 132 ( s acituzumab govitecan ) is a late - stage therapy focused on providing the targeted delivery of a drug by an antibody to treat various

  8. Slide 8: Positive Phase 2 results in TNBC patients

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 • Confirmed additional positive results for TNBC patients enrolled in Phase 2 clinical trial of IMMU - 132 – Reported Phase 2 clinical trial data in 8

  9. Slide 9: IMMU-132 Expected to Drive Near-Term Value Creation

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 9 IMMU - 132 Expected to Drive Near - Term Value Creation IMMU - 132 achieving critical milestones and well - positioned to realize full potential Ove

  10. Slide 10: Broad and robust strategic process

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 x Conducting broad and robust strategic process with the assistance of our outside financial advisor, Greenhill & Co., to expeditiously maximize stock

  11. Slide 11: Independent Analysts Support Strategy and Recent Developments on IMMU-132

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 11 Independent Analysts Support Strategy and Recent Developments on IMMU - 132 • “R&D day highlighted IMMU - 132's promise in urothelial , lung, and T

  12. Slide 12: Robust Pipeline of Antibody-Based Therapies

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Robust Pipeline of Antibody - Based Therapies Therapy Treatment Purpose Phase 3 Epratuzumab ( humanized anti - CD22) Pediatric acute lymphoblastic leu

  13. Slide 13: Greenhill: A Unique Investment Banking Firm

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Greenhill: A Unique Investment Banking Firm Founded 1996 13 How We Are Different Global Reach Selected Recent Assignments Advising Clients is Our Only

  14. Slide 14: Greenhill's Role in the Immunomedics Process

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Greenhill’s Role in the Immunomedics Process Overview 14 • In September 2016, Greenhill was engaged to conduct a comprehensive review of Immunodemics

  15. Slide 15: New, Highly Respected, Experienced and Completely Independent Board

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 New, Highly Respected, Experienced and Completely Independent Board Focused on Best Interests of All Stockholders 15

  16. Slide 16: New, Highly Experienced and Independent Board

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 16 New, Highly Experienced and Independent Board The new Immunomedics Board has the right expertise and history of staunch stockholder advocacy to max

  17. Slide 17: New, Highly Experienced and Independent Board

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 17 New, Highly Experienced and Independent Board The new Immunomedics Board has the right expertise and history of staunch stockholder advocacy to max

  18. Slide 18: New, Highly Experienced and Independent Board

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 18 New, Highly Experienced and Independent Board The new Immunomedics Board has the right expertise and history of staunch stockholder advocacy to max

  19. Slide 19: New, Highly Experienced and Independent Board

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 19 New, Highly Experienced and Independent Board The new Immunomedics Board has the right expertise and history of staunch stockholder advocacy to max

  20. Slide 20: Enhanced Corporate Governance

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 20 Enhanced Corporate Governance The new Immunomedics Board continues to take steps to strengthen governance, oversight and stockholder democracy • Ne

  21. Slide 21: Strong Stockholder Rights

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 21 Strong Stockholder Rights Annually elected Board No poison pill Stockholders can act by written consent Stockholders holding 20% can call special m

  22. Slide 22: Dissident Seeks Board Control Without Paying Any Control Premium

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 Dissident Seeks Board Control Without Paying Any Control Premium and Would Cause Disruptions Without Any Plan - Derailing Critical Near - Term Value C

  23. Slide 23: Election of venBio Nominees Will Disrupt Progress of IMMU-132

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 23 Election of venBio Nominees Will Disrupt Progress of IMMU - 132 and Derail Imminently Expected Value Creation • Handing Board control to venBio wou

  24. Slide 24: venBio Change of Control Will Have Significant Consequences

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 24 venBio Change of Control Will Have Significant Consequences • venBio's four nominees would effect a costly change in control of the Board causing m

  25. Slide 25: Immunomedics Engaged Constructively with venBio and Took Action to Achieve a Settlement

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 25 Immunomedics Engaged Constructively with venBio and Took Action to Achieve a Settlement • venBio did not engage in discussions with the Company reg

  26. Slide 26: Immunomedics Offered Multiple, Generous Settlement Options

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 26 Immunomedics Engaged Constructively with venBio by Offering Multiple , Generous Settlement Options • Prior to appointing the new Board, Immunomedic

  27. Slide 27: venBio is Seeking Control Without Paying a Control Premium

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 venBio is Seeking C ontrol W ithout Paying a Control Premium to All Stockholders • If elected, venBio’s nominees would control a majority of the Immun

  28. Slide 28: IMMU Stockholders Have a Clear Choice – Vote the WHITE Proxy Card

    0 57 166 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 28 IMMU Stockholders Have a Clear Choice – Vote the WHITE Proxy Card x Clear plan and path to accelerated approval of IMMU - 132 in TNBC patients x Br

  29. Slide 29: Vote the WHITE Proxy Card Today

    66 0 36 108 31 63 125 215 208 196 255 76 0 252 145 63 252 174 113 0 24 70 175 165 147 171 176 186 131 126 116 114 90 48 242 242 242 213 227 255 VOTE THE WHITE PROXY CARD TODAY Vote FOR all the Immunomedics director nominees If you have already voted for venBio on a gold proxy card, it is not too lat

Immunomedics — Proxy Contest (January 2017) on 6ix